CST-3056

Phase 2Small molecule

CCuraSen Therapeutics, Inc.

CST-3056 is one of 7 small molecule programs targeting Orthostatic Hypotension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic HypotensionActive, not recruiting

Orthostatic HypotensionPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Orthostatic Hypotension

#DrugCompanyPhaseTrials

Northera

Lundbeck

Approved

10 2

Proamatine

Takeda

Approved

7 3

Corlanor

Amgen

Approved

—4

Inderal

WWyeth-Lederle Vaccines

Mestinon

1 6

CST-3056

CCuraSen Therapeutics, Inc.

Phase 2

1 7

Midodrine or Atomoxetine Pill

VVanderbilt University Medical Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Orthostatic Hypotension

NCT07089043

Clinical

Trials by Indication[1]

Orthostatic Hypotension1 trial

A Single-Blind Dose-Ranging Study in Subjects With Neurogenic Orthostatic Hypotension to Evaluate the Effect of CST-3056 on Symptoms and Signs of Orthostatic Hypotension

Active, not recruiting·CCuraSen Therapeutics, Inc.·Phase 2·NCT07089043·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CST-3056. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CST-3056 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CST-3056. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CuraSen Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCuraSen Therapeutics, Inc.

CST-3056

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Orthostatic Hypotension1 trial

References

Drug Info

Quick Facts

Related News